Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer (LiverMWA1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00922181 |
Recruitment Status :
Completed
First Posted : June 17, 2009
Last Update Posted : November 16, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Neoplasms | Device: Microwave ablation Device: Radiofrequency ablation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 19 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible |
Study Start Date : | August 2008 |
Actual Primary Completion Date : | April 2009 |
Actual Study Completion Date : | April 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: MWA
Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
|
Device: Microwave ablation
Liver tumors are destructed/ablated using single-probe microwave energy device
Other Name: MW ablation antenna (VT2237) and a 915 MHz Valleylab MW generator (VTSYS3; Covidien, Europe NV) |
Active Comparator: RFA
Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
|
Device: Radiofrequency ablation
Liver tumors are destructed/ablated using radiofrequency energy device |
- Variability of ablation diameters [ Time Frame: within the first 7 days and 3 months after surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Unresectable metastatic liver cancer
- No invasion of major biliary structures
- No invasion of major vascular structures
- ASA score < 4
- WHO score 0-1
- Pre-operative chemotherapy is allowed
Exclusion Criteria:
- Resectable liver metastases
- Life expectancy less than 3 months
- Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials
- Coagulopathy with platelet count less than 50000
- Active infectious disease
- Age below 18 years
- Pregnancy of breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00922181
Belgium | |
University Hospital Gasthuisberg | |
Leuven, Vlaams-Brabant, Belgium, 3000 |
Principal Investigator: | Baki Topal, MD, PhD | Universitaire Ziekenhuizen Leuven |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University Hospital Gasthuisberg Leuven |
ClinicalTrials.gov Identifier: | NCT00922181 History of Changes |
Other Study ID Numbers: |
kulasMWA1 |
First Posted: | June 17, 2009 Key Record Dates |
Last Update Posted: | November 16, 2009 |
Last Verified: | November 2009 |
Keywords provided by University Hospital, Gasthuisberg:
malignancy liver microwave surgery |
Additional relevant MeSH terms:
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Liver Diseases Liver Extracts Hematinics |